- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
35
35 companies
Travere Therapeutics
Market Cap: US$3.6b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$40.09
7D
-2.1%
1Y
140.1%
Zevra Therapeutics
Market Cap: US$610.0m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$10.49
7D
1.6%
1Y
44.7%
Axsome Therapeutics
Market Cap: US$9.4b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$186.42
7D
1.2%
1Y
78.9%
Madrigal Pharmaceuticals
Market Cap: US$12.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$529.14
7D
2.0%
1Y
71.4%
Syndax Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$22.08
7D
-9.2%
1Y
69.8%
Insmed
Market Cap: US$30.4b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$144.48
7D
-1.5%
1Y
104.1%
Rhythm Pharmaceuticals
Market Cap: US$5.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$85.18
7D
-3.0%
1Y
42.3%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$6.02
7D
-4.4%
1Y
24.1%
Aldeyra Therapeutics
Market Cap: US$101.1m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.70
7D
-7.1%
1Y
-29.8%
Capricor Therapeutics
Market Cap: US$2.0b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$35.00
7D
-0.1%
1Y
166.2%
ARS Pharmaceuticals
Market Cap: US$778.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.40
7D
4.7%
1Y
-41.6%
Pelthos Therapeutics
Market Cap: US$77.2m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$23.00
7D
0%
1Y
67.9%
AC Immune
Market Cap: US$284.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.06
7D
-2.5%
1Y
93.7%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.75
7D
-3.4%
1Y
64.4%
Kiniksa Pharmaceuticals International
Market Cap: US$3.3b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$43.04
7D
-6.2%
1Y
106.1%
CG Oncology
Market Cap: US$6.1b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$69.88
7D
3.3%
1Y
237.1%
Verrica Pharmaceuticals
Market Cap: US$108.6m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$6.51
7D
10.1%
1Y
41.8%
Vera Therapeutics
Market Cap: US$2.9b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$40.27
7D
-7.3%
1Y
80.3%
Belite Bio
Market Cap: US$6.5b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$167.42
7D
-0.8%
1Y
184.7%
SIGA Technologies
Market Cap: US$318.1m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.51
7D
-4.0%
1Y
-27.7%
BeOne Medicines
Market Cap: US$34.6b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$312.41
7D
-2.4%
1Y
25.4%
Praxis Precision Medicines
Market Cap: US$9.5b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$337.29
7D
-0.8%
1Y
821.8%
Unicycive Therapeutics
Market Cap: US$182.0m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$7.71
7D
10.6%
1Y
21.6%
Gyre Therapeutics
Market Cap: US$718.6m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.73
7D
-3.6%
1Y
-15.9%
Mirum Pharmaceuticals
Market Cap: US$5.6b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$94.31
7D
-2.2%
1Y
138.0%
Fortress Biotech
Market Cap: US$71.8m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.25
7D
-7.4%
1Y
42.4%
Fennec Pharmaceuticals
Market Cap: US$225.5m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.68
7D
2.8%
1Y
18.2%
Journey Medical
Market Cap: US$134.5m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$5.04
7D
-4.9%
1Y
-32.6%
Benitec Biopharma
Market Cap: US$451.5m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$12.96
7D
-4.7%
1Y
-5.1%
Legend Biotech
Market Cap: US$4.7b
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
LEGN
US$25.93
7D
26.4%
1Y
-24.4%
Inovio Pharmaceuticals
Market Cap: US$92.6m
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
INO
US$1.14
7D
-4.2%
1Y
-39.0%
Protagonist Therapeutics
Market Cap: US$6.8b
Operates as a discovery and development company in the United States.
PTGX
US$105.55
7D
0.1%
1Y
128.7%
Dyadic International
Market Cap: US$30.5m
A biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally.
DYAI
US$0.83
7D
-5.2%
1Y
-31.4%
Geron
Market Cap: US$961.4m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.55
7D
-8.3%
1Y
11.5%
Prothena
Market Cap: US$574.4m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$10.72
7D
-0.9%
1Y
11.8%